<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02319824</url>
  </required_header>
  <id_info>
    <org_study_id>2721.00</org_study_id>
    <secondary_id>NCI-2014-02154</secondary_id>
    <secondary_id>2721</secondary_id>
    <secondary_id>2721.00</secondary_id>
    <secondary_id>K23CA175167</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT02319824</nct_id>
  </id_info>
  <brief_title>NY-ESO-1-Specific T-cells in Treating Patients With Advanced NY-ESO-1-Expressing Sarcomas Receiving Palliative Radiation Therapy</brief_title>
  <official_title>A Pilot Trial of NY-ESO-1-Specific T Cells in Patients With Metastatic NY-ESO-1-Expressing Sarcomas Receiving Palliative Radiation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot, phase I trial studies the safety of cancer-testis antigen (NY-ESO-1)-specific T
      cells (a type of immune cell) in treating patients with NY-ESO-1-expressing sarcomas that
      have spread to other places in the body and are receiving palliative (relief of symptoms and
      suffering caused by cancer) radiation therapy. Placing a modified gene for NY-ESO-1 into
      white blood cells may help the body build an immune response to kill tumor cells that express
      NY-ESO-1. Palliative radiation therapy may help patients with advanced sarcoma live more
      comfortably. Giving NY-ESO-1-specific T cells following palliative radiation therapy may be a
      better treatment for patients with sarcomas.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To evaluate the safety and toxicity of NY-ESO-1-specific T cells when given following
      high-dose, hypo-fractionated palliative radiation to patients with advanced NY-ESO-1
      expressing sarcomas.

      SECONDARY OBJECTIVES:

      I. To look for preliminary evidence of systemic efficacy of NY-ESO-1-specific T-cell therapy
      following radiation on non-radiated tumors.

      II. To determine whether radiation increases trafficking of adoptively transferred
      NY-ESO-1-specific T cells by comparing tumor biopsy specimens from radiated and non-radiated
      tumors.

      OUTLINE:

      Patients undergo palliative radiation therapy at the discretion of the treating radiation
      oncologist. Patients then receive NY-ESO-1-specific T cells intravenously (IV) over 60
      minutes 2-3 days after completion of radiation therapy.

      After completion of study treatment, patients are followed up weekly for 2 weeks, at 4-6, 8,
      10, and 12 weeks, and then for up to 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events Measured by the National Cancer Institute Common Terminology Criteria for Adverse Events Version (v)4.03</measure>
    <time_frame>Up to 12 weeks post-treatment</time_frame>
    <description>CTCAE v4.03</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>T Cell Transfer Based on Response Evaluation Criteria In Solid Tumors v1.1</measure>
    <time_frame>At 6 weeks post-treatment</time_frame>
    <description>RECIST at 6 weeks after treatment (non-radiated tumors only)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transferred NY-ESO-1-specific T Cells Based on Flow Cytometry Using Major Histocompatibility Complex Tetramers</measure>
    <time_frame>Up to 6 weeks post-treatment</time_frame>
    <description>Over 5% tet+ cells at 6 weeks? Patients may have detectable NY-ESO-1 specific T cells by MHC tetramers but if they are less than 5% this will be considered negative.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>Treatment (radiation and NY-ESO-1-specific T cells)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo palliative radiation therapy at the discretion of the treating radiation oncologist. Patients then receive NY-ESO-1-specific T cells IV over 60 minutes 2-3 days after completion of radiation therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous NY-ESO-1-specific CD8-positive T Lymphocytes</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (radiation and NY-ESO-1-specific T cells)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (radiation and NY-ESO-1-specific T cells)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Palliative Radiation Therapy</intervention_name>
    <description>Undergo palliative radiation therapy</description>
    <arm_group_label>Treatment (radiation and NY-ESO-1-specific T cells)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        INCLUSION CRITERIA FOR SCREENING:

          -  Histopathological documentation of sarcoma

          -  Patients must express NY-ESO-1 in their tumor by immunohistochemistry (IHC) (&gt; 5%)
             prior to leukapheresis

          -  For leukapheresis, patients must meet the following criteria (any exceptions to this
             will require prior approval by the apheresis director and principal investigator
             [PI]):

          -  Pulse &gt; 45 or &lt; 120

          -  Weight &gt;= 45 kg

          -  Temperature =&lt; 38° Celsius (C) (=&lt; 100.4° Fahrenheit [F])

          -  White blood cell count (WBC) &gt;= 2,000

          -  Hematocrit (HCT) &gt;= 30%

          -  Platelets &gt;= 75,000

        INCLUSION CRITERIA FOR TREATMENT:

          -  A diagnosis of a metastatic or unresectable sarcoma

          -  Patient must have a biopsy-accessible tumor to be radiated

          -  Patient must have consulted with a radiation oncologist who is planning radiation;
             their radiation oncologist should have documented plans to administer a dose of at
             least 30 Gy in 5 or fewer fractions

          -  Human leukocyte antigen (HLA) type A0201 or A2402

          -  Zubrod (Eastern Cooperative Oncology Group [ECOG]) performance status of '0-2'

          -  All patients must have an electrocardiogram (ECG) within 2 weeks of starting
             conditioning

          -  All patients must have an echo or multigated acquisition (MUGA) scan showing ejection
             fraction (EF) &gt; 50% and normal troponin and creatine kinase MB (CK MB) performed
             within 90 days of starting treatment

        Exclusion Criteria:

        EXCLUSION CRITERIA FOR SCREENING:

          -  Patients who do not meet the above inclusion criteria will not receive leukapheresis

        EXCLUSION CRITERIA FOR TREATMENT:

          -  Patients with a history of proven myocarditis, pericarditis, or endocarditis

          -  Pregnant women, nursing women, men and women of reproductive ability who are unwilling
             to use effective contraception or abstinence; women of childbearing potential must
             have a negative pregnancy test within two weeks prior to study entry

          -  Inadequate renal function as indicated by serum creatinine &gt;= 1.5 times the upper
             limit of normal

          -  Inadequate liver function as indicated by total bilirubin &gt;= 1.5 times the upper limit
             of normal

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) &gt;= 2.5 times the
             upper limit of normal

          -  Active symptomatic congestive heart failure

          -  Clinically significant hypotension

          -  Newly diagnosed cardiac arrhythmia; patients with an arrhythmia that has been stable
             for at least 3 months will be allowed to participate

          -  Known untreated central nervous system (CNS) metastasis

          -  Patients with systemic infections requiring antibiotics or chronic
             maintenance/suppressive therapy

          -  Patients receiving systemic anticancer therapy (chemotherapy, &quot;biologics&quot;,
             immunotherapy) less than 2 weeks prior to starting radiation

          -  Clinically significant autoimmune disorders requiring on-going systemic
             immune-suppression for control

          -  Patients with acquired immunodeficiency syndrome (AIDS) or who are known to be human
             immunodeficiency virus (HIV) positive are not eligible for this study; testing may
             have been done up to 3 months prior to treatment

          -  Current treatment with steroids

          -  Known infection with hepatitis B virus (HBV) and hepatitis C virus (HCV); testing may
             have been done up to 3 months prior to treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seth Pollack</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2014</study_first_submitted>
  <study_first_submitted_qc>December 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2014</study_first_posted>
  <results_first_submitted>April 18, 2017</results_first_submitted>
  <results_first_submitted_qc>April 18, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 5, 2017</results_first_posted>
  <last_update_submitted>April 18, 2017</last_update_submitted>
  <last_update_submitted_qc>April 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fred Hutchinson Cancer Research Center</investigator_affiliation>
    <investigator_full_name>Seth Pollack</investigator_full_name>
    <investigator_title>Responsible Party</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Radiation and NY-ESO-1-specific T Cells)</title>
          <description>Patients undergo palliative radiation therapy at the discretion of the treating radiation oncologist. Patients then receive NY-ESO-1-specific T cells IV 2-3 days after completion of radiation therapy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Radiation and NY-ESO-1-specific T Cells)</title>
          <description>Patients undergo palliative radiation therapy at the discretion of the treating radiation oncologist. Patients then receive NY-ESO-1-specific T cells 2-3 days after completion of radiation therapy.
Autologous NY-ESO-1-specific CD8-positive T Lymphocytes</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40" lower_limit="27" upper_limit="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Adverse Events Measured by the National Cancer Institute Common Terminology Criteria for Adverse Events Version (v)4.03</title>
        <description>CTCAE v4.03</description>
        <time_frame>Up to 12 weeks post-treatment</time_frame>
        <population>treated patients</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Radiation and NY-ESO-1-specific T Cells)</title>
            <description>Patients undergo palliative radiation therapy at the discretion of the treating radiation oncologist. Patients then receive NY-ESO-1-specific T cells I60 minutes 2-3 days after completion of radiation therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Events Measured by the National Cancer Institute Common Terminology Criteria for Adverse Events Version (v)4.03</title>
          <description>CTCAE v4.03</description>
          <population>treated patients</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 1 Rash (likely related)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2 Shortness of breath (possibly related)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2 Cough (possibly related)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1 Cough (probably related)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>T Cell Transfer Based on Response Evaluation Criteria In Solid Tumors v1.1</title>
        <description>RECIST at 6 weeks after treatment (non-radiated tumors only)</description>
        <time_frame>At 6 weeks post-treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Radiation and NY-ESO-1-specific T Cells)</title>
            <description>Patients undergo palliative radiation therapy at the discretion of the treating radiation oncologist. Patients then receive NY-ESO-1-specific T cells 2-3 days after completion of radiation therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>T Cell Transfer Based on Response Evaluation Criteria In Solid Tumors v1.1</title>
          <description>RECIST at 6 weeks after treatment (non-radiated tumors only)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>SD</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>PD</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transferred NY-ESO-1-specific T Cells Based on Flow Cytometry Using Major Histocompatibility Complex Tetramers</title>
        <description>Over 5% tet+ cells at 6 weeks? Patients may have detectable NY-ESO-1 specific T cells by MHC tetramers but if they are less than 5% this will be considered negative.</description>
        <time_frame>Up to 6 weeks post-treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Radiation and NY-ESO-1-specific T Cells)</title>
            <description>Patients undergo palliative radiation therapy at the discretion of the treating radiation oncologist. Patients then receive NY-ESO-1-specific T cells 2-3 days after completion of radiation therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Transferred NY-ESO-1-specific T Cells Based on Flow Cytometry Using Major Histocompatibility Complex Tetramers</title>
          <description>Over 5% tet+ cells at 6 weeks? Patients may have detectable NY-ESO-1 specific T cells by MHC tetramers but if they are less than 5% this will be considered negative.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Number of patients with &lt;5% of CD8 T cells tet+</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;5%</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <desc>CTCAE v4.03</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Radiation and NY-ESO-1-specific T Cells)</title>
          <description>Patients undergo palliative radiation therapy at the discretion of the treating radiation oncologist. Patients then receive NY-ESO-1-specific T cells 2-3 days after completion of radiation therapy.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE v4.03</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cough</sub_title>
                <description>2 separate events in 1 patient, one grade 1 and one grade 2</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>shortness of breath</sub_title>
                <description>grade 2</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <description>grade 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This trial was ended early as persistence was not at the level we had hoped and we had the opportunity to pursue a more promising strategy.
The data is limited by having only 2 patients.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Seth Pollack</name_or_title>
      <organization>Fred Hutchinson Cancer Research Center</organization>
      <phone>206-667-6629</phone>
      <email>spollack@fhcrc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

